AbbVie's Reduced Commentary on Humira Amid Biosimilar Competition
AbbVie has significantly reduced its detailed commentary about the performance of its flagship drug, Humira. In a July 2026 earnings call, management provided only one sentence update regarding global sales of $706 million—a 36.1% decline on an operational basis—compared to more in-depth explanations earlier in 2024 and 2025 when the drug's performance was deteriorating faster than expected due to biosimilar competition. Instead, AbbVie has shifted focus toward its newer growth drivers such as Skyrizi ($5.5 billion Q2 sales) and Rinvoq (over $2.5 billion in revenue), both of which are growing at a rate above 20%. The company also recently acquired Apogee Therapeutics to bolster its pipeline. While the decline in Humira is slowing, it still accounts for about 4% of AbbVie's second-quarter revenues and continues to shrink. Investors should watch future earnings calls closely to see if management resumes providing more detailed updates or maintains a quiet stance.
Tickers: $ABBV
Topics: biosimilars drug sales decline pharmaceutical product diversification